These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 2541074)
1. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Jin B; Scott JL; Vadas MA; Burns GF Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074 [TBL] [Abstract][Full Text] [Related]
2. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. Kasid A; Bell GI; Director EP J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414 [TBL] [Abstract][Full Text] [Related]
3. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481 [TBL] [Abstract][Full Text] [Related]
4. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260 [TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1. Espevik T; Figari IS; Ranges GE; Palladino MA J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782 [TBL] [Abstract][Full Text] [Related]
7. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Owen-Schaub LB; Gutterman JU; Grimm EA Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408 [TBL] [Abstract][Full Text] [Related]
8. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}. Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921 [TBL] [Abstract][Full Text] [Related]
9. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes. Kondo S; Isobe K; Ishiguro N; Nakashima I; Miura T Immunology; 1993 Jul; 79(3):459-64. PubMed ID: 8406573 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. Ortaldo JR; Mason AT; O'Shea JJ; Smyth MJ; Falk LA; Kennedy IC; Longo DL; Ruscetti FW J Immunol; 1991 Jun; 146(11):3791-8. PubMed ID: 1851793 [TBL] [Abstract][Full Text] [Related]
13. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. Geller RL; Smyth MJ; Strobl SL; Bach FH; Ruscetti FW; Longo DL; Ochoa AC J Immunol; 1991 May; 146(10):3280-8. PubMed ID: 1673980 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes. Inge TH; McCoy KM; Susskind BM; Barrett SK; Zhao G; Bear HD J Immunol; 1992 Jun; 148(12):3847-56. PubMed ID: 1602133 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line. Stoeck M; Miescher S; MacDonald HR; Von Fliedner V J Cell Physiol; 1989 Oct; 141(1):65-73. PubMed ID: 2789227 [TBL] [Abstract][Full Text] [Related]
16. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. Ruegemer JJ; Ho SN; Augustine JA; Schlager JW; Bell MP; McKean DJ; Abraham RT J Immunol; 1990 Mar; 144(5):1767-76. PubMed ID: 2407783 [TBL] [Abstract][Full Text] [Related]
17. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359 [TBL] [Abstract][Full Text] [Related]
18. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha: a costimulator for cytotoxic cell differentiation. Chouaib S Nouv Rev Fr Hematol (1978); 1991; 33(6):471-5. PubMed ID: 1818300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]